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Abstract
1

Cancer is one of the leading causes of death in the United States . This disease has impacted
billions worldwide and has led to an ever-increasing burden on the healthcare system. Over the
last couple of years, researchers have improved upon conventional cancer therapy that includes
chemotherapy, radiation, and surgery. One novel approach is immunotherapy, which shows great
potential because it has the ability to directly target cancerous cells2. This is a viable treatment
because most cancers develop the ability to block immune pathways and evade the killer immune
cells in what is known as cancer immune escape. One such pathway that is inhibited during the
progression of specific cancers is the PD-L1 and PD-1 pathway thus inhibiting this pathway can
be an effective treatment of advanced cancers3. To improve upon the efficacy of certain
immunotherapies, we engineered a novel delivery method using exosomes to target this specific
pathway. We focused on exosomes due to the nanovesicles ability to penetrate tissue better, the
longer half-life of the treatment, and the biocompatibility of naturally derived vesicles. To
complete this task, we focused on successfully integrating our exosomes expression vector in
HEP-G2 and HK-2 cell lines. Next, we verified production of the engineered exosomes through
the process of cotransfection using a known exosome-specific marker vector. Our results are
valuable as they prove successful exosome plasmid vector integration. Furthermore, our study is
a proof of concept that exosomes can be manipulated to express surface proteins; having the
potential of interrupting immune evading pathways of numerous diseases.

U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission
data (1999-2016): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National
Cancer Institute; www.cdc.gov/cancer/dataviz, June 2019.
2
Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and
next steps. Nat Rev Cancer. 2011;11:805–12.
3
Wu Y, Chen W, Xu ZP and Gu W (2019) PD-L1 Distribution and Perspective for Cancer Immunotherapy— Blockade,
Knockdown, or Inhibition. Front. Immunol. 10:2022. doi: 10.3389/fimmu.2019.02022
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1. Introduction
1.1 Background and motivation
The search for a successful cancer treatment has been an ongoing pursuit. Over the last few
decades there have been many advancements but the treatments available today still cause severe
side effects that diminish the quality of life for patients. For example, conventional therapies like
chemotherapy and radiation lead to chemotherapy-induced nausea, vomiting, and peripheral
neuropathy, as well as malabsorption, weight loss, anemia, fatigue and increased risk of sepsis4.
Therefore research has pivoted its focus towards biologics, like immunotherapies, as novel
treatment options for the future. Antibody based treatments have been proven to be more
effective at reducing side effects than conventional therapies, but they still have their limitations.
Oftentimes antibody therapies cause the immune system to attack healthy cells resulting in
adverse effects from an overactive autoimmune response5. For this reason we want to explore the
possibility of an engineered biocompatible nanoparticle immunotherapy, inspired by exosomes
and their unique ability to penetrate tissue membrane barriers.

1.2 Literature review
1.2.1 Overview of the Immune System
The immune system, as humans experience it, has two main subdivisions. The first is the innate
immune system response which refers to a variably-nonspecific and fast-acting defense
mechanism. This includes physical barriers such as the skin, chemicals in the blood, and immune
system cells that attack foreign cells in the body. The active cells of the innate immune system
recognize general features of pathogens, like bacterial cell walls, and include cells like
macrophages, neutrophils,dendritic cells, natural killer cells, mast cells, and basophils6. The other
subdivision is the adaptive immune system response and it is much more specific and complex.
Adaptive immunity is considered the second line of defense because it is initiated if the innate
immune response is unable to completely combat the invading pathogen. The main cells of the
adaptive immune response, T-cells and B-cells, originate in our bone marrow and mature at
different locations in the body. The cells may float around in the bloodstream or lymphatic
system or take up residence in an organ or tissue. The specific immune response has four
defining characteristics; antigen specificity, diverse recognition range, memory immunity, and

4

Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve
Tolerance and Reduce Sequelae?. Frontiers in pharmacology, 9, 245. https://doi.org/10.3389/fphar.2018.00
5
Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., Levitt, M.,
Asif, A., & Hossain, M. A. (2019). Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and
Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. Journal of clinical medicine
research, 11(4), 225–236. https://doi.org/10.14740/jocmr3750
6
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New
York: Garland Science; 2001.
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self:non-self discrimination7. The innate immune system and adaptive immune system work
together to monitor the body looking for abnormalities and maintaining the homeostatic
standard.
An important concept to understand is how the immune system determines a cell to be unhealthy
or pathogenic, resulting in cell death. Although the intercellular communication is much more
complex, the foundational concept of how immune cells determine which cells to kill based on
presented immune-evasion surface biomarkers is illustrated in figure 1 below.

Figure 1. Natural killer (NK) cells recognize the MHC I receptor on healthy cells. If MHC I
is absent, the cell is lysed. This figure is adapted from Concepts of Biology.8
1.2.2 Cancer is a Complex Disease to Treat
When cells become mutated, they usually appear to the immune cells as abnormal. The body
then recognizes them as non-self or foreign because the proper immune-evasion surface
biomarkers are not presented. By eliminating cells that have become abnormal, the immune
system helps to protect against cancer. However, if the cells mutate enough so that they are able
to escape the surveillance mechanisms of the immune system, and they may continue to
10
reproduce as cancer cells9. Cancer is one of the leading causes of death in the United States .
This disease has impacted billions worldwide and has led to an ever-increasing burden on the
healthcare system. Over the last couple of years, researchers have improved upon conventional
cancer therapy that includes chemotherapy, radiation, and surgery but it still proves very difficult
to treat.
Cancer is the uncontrolled growth of abnormal cells in the body and these cells have distinct
characteristics that make them so difficult to treat. A main hurdle when trying to treat cancer is
that it develops a kind of immortality. In culture malignant cells have shown to live for an
Charles Janeway, Paul Travers, Mark Walport and Mark Schlomchik. Immunobiology. (2004) 6th Edition. Garland Publishing,
NY, NY
8
Concepts of Biology - 1st Canadian Edition by Charles Molnar and Jane Gair
9
The Immune System. (n.d.). Retrieved from https://www.cancerquest.org/cancer-biology/immune-system
10 
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission
data (1999-2016): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National
Cancer Institute; www.cdc.gov/cancer/dataviz, June 2019.
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indefinite number of population doublings which is alarming compared to their normal diploid
cell counterparts. It is not clear what limits the life expectancy of normal diploid cells in culture,
but it may be related to the continual shortening of chromosome telomeres each time cells divide.
Cancerous cells on the other hand are known to have elevated levels of telomerase that maintain
telomere length and extend their overall possible life and probability to become tumors.11 Cancer
also does not exhibit unique biomarkers , making it difficult to find possible drug targets that
would not cause adverse healthy cell death. The most difficult hurdle when trying to treat cancer
is its ability to evade the immune system, an ability also known as immune escape.
1.2.3 Overview of Immune escape and the PD1 PD-L1 pathway mechanisms
Under normal conditions, the immune system can activate an anticancer immune response and
induce cancer cell death, known as the cancer immunity cycle7. First, tumor cells produce
mutated antigens that are captured and phagocytosed by antigen-presenting cells (APCs) called
dendritic cells. Next, the dendritic cells prime T cells with the tumor antigen, stimulating its
differentiation into activated cytotoxic T cells. These activated cytotoxic T cells then travel to the
tumor, infiltrate its microenvironment, recognize, and bind to the surface of cancer cells. Lastly,
the bound killer T cells release cytotoxins, inducing apoptosis in their target cancer cells. This
process is depicted in figure 2 below; and this process would be an ideal response

Figure 2. Cancer-immunity Cycle - Immuno Oncology Tumor Micro Environment. Image pulled
from DMCA complaint PNG library12
11 

Ruddon RW. What Makes a Cancer Cell a Cancer Cell? In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.
12
https://www.seekpng.com/ipng/u2e6t4a9u2q8e6i1_cancer-immunity-cycle-immuno-oncology-tumor-micro-environment/"
target="_blank">Cancer-immunity Cycle - Immuno Oncology Tumor Micro Environment
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Although there are several ways that tumor cells may get around the immune defenses of the
body. Many cancers produce chemical messengers that inhibit the actions of immune cells. Other
cancers have defects in the way that antigens are presented on their cell surface. An example of
this can be seen in the T-cells tightly regulated PD1-PDL1 pathway mechanisms. This pathways
helps to ensure activation or deactivation of the immune system at the appropriate times to
13
minimize autoimmune reactions . PDL1 is expressed on the surface of healthy cells to avoid
their death during an immune response. However, many cancers have evolved to express PD-L1
on their surface as well to hijack these built in controls to prevent the immune response and
avoid cell death, this is called immune escape.

Figure 3. PD-1/PD-L1 Mechanism. The interaction between a T cell and a Tumor Cells via the
PD-1/PD-L1 pathway14. This image is adapted and modified from the FDA.
1.2.4 PD-1 PD-L1 dependent cancers
Since 1992 when Yasumasa Ishida, Tasuku Honjo and colleagues at Kyoto University discovered the
PD-1 receptor there has been vast research on which cancers typically hijack this programmed death
pathway in order to hide inside the body. Understanding what cancers are dependent on the PD-1 and
13 

Cancer Immunotherapy: PD-1 and Beyond. (2020). Retrieved https://www.smartpatients.com/targets/pd-1.
Center for Drug Evaluation and Research. (2019, February 22). Determining Clinical Benefits of Treatment with Checkpoint
Inhibitors. Retrieved May 30, 2020, from https://www.fda.gov/drugs/regulatory-science-action/impact-story-determiningclinical-benefit-treatment- beyond-progression-immune-checkpoint-inhibitors
14
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PD-1 mechanism can improve the survival rate of cancer patients as the cancer treatments prove to work
better when the therapy also targets this specific pathway. As of this year, the use of checkpoint inhibitors
are possibly the most understood and successful immunotherapy discovered at this point in cancer
therapy. Some cancers that manipulate the PD-1 pathway include bladder cancer, breast cancer, lung
cancer, kidney cancer, skin cancer, colorectal cancer, head and neck cancer, lymphoma, cervical cancer,
esophageal cancer, and stomach cancer15. Moreover, there are specific uses of this immunotherapy that
affects the PD-1/PD-L1 checkpoint such as s quamous cell carcinoma of the head and neck16, glioma

tumors17, EGFR-Driven Lung Tumors18, and chronic infection-induced cytotoxic T lymphocyte

exhaustion19. Thus, it is imperative to optimize immunotherapies that target PD-1/PD-L1 as they can be
used to fight numerous cancer types.

1.2.5 Immunotherapy
Our novel approach involves immunotherapy, which helps the immune system to fight the
cancer. There are also many types of immunotherapies which include cancer vaccines,
nonspecific immunotherapies, monoclonal antibodies, and checkpoint inhibitors, with the latter
two being our strategic focus20. Moreover, the benefits of these immunotherapies over
conventional therapies are that they can help to bolster treatments by being used in combination
with other therapies and that they are effective when other treatments are not20. In addition,
cancer is less likely to return due to immunomemory, and immunotherapy results in fewer
systemic side effects related to conventional therapies20. These benefits all greatly improve
patient outcomes.
1.2.6 Exosomes have therapeutic potential
Once thought to be a system of cellular waste elimination, exosomes have recently been
characterized as a model for cell-cell communication, revitalizing interest in their drug delivery
capacity.21 Exosomes are naturally occurring nano-biovesicles secreted by the cells in our body
that can transport cell-specific cargo. Unlike liposomes and other synthetic nanoparticle vehicles,
exosomes contain transmembrane and membrane-bound proteins that could promote the

15

Luke, J., & Cancer Research Institute. (2020). Immunomodulators: Checkpoint Inhibitors, Cytokines, Agonists, Adjuvants.
Retrieved May 27, 2020, from https://www.cancerresearch.org/immunotherapy/treatment-types/immunomodulators
16
Zandberg, D. P., & Strome, S. E. (2014). The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and
neck. Oral oncology, 50( 7), 627–632. https://doi.org/10.1016/j.oraloncology.2014.04.003
17
Filippova N, Yang X, An Z, Nabors LB, Pereboeva L. Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a
Potential Strategy for Glioma Treatment. J Cancer Sci Ther. 2018;10(8):190-197. doi:10.4172/1948-5956.1000543
18
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., … Wong, K.-K. (2013). Activation of
the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 3( 12), 1355 LP – 1363.
https://doi.org/10.1158/2159-8290.CD-13-0310
19
Hofmeyer, K. A., Jeon, H., & Zang, X. (2011). The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T
Lymphocyte Exhaustion. Journal of Biomedicine and Biotechnology, 2011, 451694. https://doi.org/10.1155/2011/451694
20
Media, H. (2019, March 25). Immunotherapy: Side Effects, Risks & Benefits. Retrieved from
https://www.cancertherapyadvisor.com/home/tools/fact-sheets/immunotherapy-side-effects-risks-and-benefits/
21
Lasser C, O’Neil SE, Shelke GV, Sihlbom C, Hansson SF, Gho YS, Lundback B, Lotvall J. Exosomes in the nose induce
immune cell trafficking and harbour an altered protein cargo in chronic airway inflammation. J Transl Med. 2016;14(1):181.
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endocytosis and delivery of their internal content.22 Exosomes carrying cell-specific cargo of
proteins, lipids, and nucleic acids may act as a novel intercellular communication mechanism.
This concept is based on the observation that exosomes released from parental cells may interact
with target cells, leading to the subsequent influence of target cell behavior and phenotypic
features23. Exosomes have been pursued because they show targeted delivery within the body
and are even able to pass the blood-brain barrier. They may display distinct tissue/cell homing as
a result of their high expression of adhesion molecules such as integrins and tetraspanins, giving
them their potential target capability24. Once exosomes are internalized there is horizontal
genetic transfer of their content to the cytoplasm of the target cells.
Knowing this we would like to utilize the exosomes homing abilities to inhibit a cancer cell’s
ability to escape the body’s immune response by blocking the escape pathway via surface
expression of PDL1-scFV, blocking the PD-L1 and PD-1 pathway. In the future, there should be
an investigation into the engineered exosomes potential to deliver target-cell nanomedicine, a
build off of our project that would make the treatment even more effective.
1.2.7 Exosome Biogenesis
Exosomes are produced in the endosomal compartment of most eukaryotic cells. They originate
from multivesicular bodies (MVBs), a specialised subset of endosomes that contain
membrane-bound intraluminal vesicles (ILVs) which form by budding into the lumen of these
MVBs25. The content of MVBS, ILVs, can either be degraded through fusion with lysosomes or
released into the extracellular space as exosomes through fusion with the plasma membrane25, 26.
1.2.8 Tetraspanins
Tetraspanins are membrane-bound proteins with a unique structure that play an important role in cellular
signal transduction27. Simply, tetraspanins organize membrane proteins for cell-to-cell communication.
Thus, they are paramount in the creation of exosomes, nanovesicle-shuttles for signal molecules.The
transmembrane structure of tetraspanins allows for inner and outer surface display modifications,

which is necessary for engineering exosomes as well as enables the study of exosomes via
fluorescent probes.28  For our project, in the exosomes’ expression vector exploits CD8 tetraspanin

Gonzalez-Calero L, Martin-Lorenzo M, Alvarez-Llamas G. Exosomes: a potential key target in cardio-renal syndrome. Front
Immunol. 2014;5:465.
23
Schneider, A., & Simons, M. (2013). Exosomes: vesicular carriers for intercellular communication in neurodegenerative
disorders. Cell and tissue research, 352(1), 33–47. https://doi.org/10.1007/s00441-012-1428-2
24
Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9(1):40–55. doi:
10.1038/nrc2543.
25
Multivesicular bodies. (n.d.). Retrieved from https://www.nature.com/subjects/multivesicular-bodies
26
Exosome (vesicle). (2020, May 19). Retrieved from https://en.wikipedia.org/wiki/Exosome_(vesicle)
27
Termini, C. M., & Gillette, J. M. (2017). Tetraspanins Function as Regulators of Cellular Signaling . Frontiers in Cell and
Developmental Biology , Vol. 5, p. 34. Retrieved from https://www.frontiersin.org/article/10.3389/fcell.2017.00034
28
Stickney Z, Losacco J, McDevitt S, Zhang Z, Lu B. Development of exosome surface display technology in living human cells.
Biochem Biophys Res Commun. 2016;472(1):53-59. doi:10.1016/j.bbrc.2016.02.058
22
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while we use CD63, a tetraspanin specific to exosomes, to verify the secretion of the engineered
exosomes.

1.3 Current Checkpoint Inhibiting Immunotherapies and their drawbacks
Anti PD-1 or anti PD-L1 antibodies can prevent the cancer tumor cell from binding to PD-1 and
thus allow T cells to remain active. Table 1 depicts the mAb checkpoint inhibitors that are
currently being used as cancer immunotherapy. For example Keytruda, an anti-PD1 inhibitor is
specifically FDA- approved for the treatment of metastatic non-small cell lung cancer and head
and neck squamous cell carcinoma. And Tecentriq is an anti PD-L1 inhibitor FDA approved to
treat cancers like urothelial carcinoma and non-small cell lung cancer. These drugs have been
shown to be helpful in treating several types of cancer, and new cancer types are being added as
more studies show these drugs to be effective29. However, one drawback of these
immunotherapies is that it can over activate the immune system and cause off targeting where
the immune system attacks healthy cells resulting in serious adverse effects known as
immune-related adverse events (irAEs)5, 30. The spectrum of organ systems affected by irAEs is
very broad, as such toxicities can affect almost any organ, with varying frequencies and
severities30. Examples of these toxicities range from minor symptoms of inflammation (e.g.,
fever) to major conditions similar to autoimmune disorders like pneumonitis (inflamed lungs),
hepatitis (inflamed kidneys), encephalitis (inflamed brain), and myocarditis (inflamed heart
muscle)30. Other limitations include rapid clearance rates and low tissue penetration31.

29

Immune Checkpoint Inhibitors and Their Side Effects. (2019, December 27). Retrieved from
https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.htm
l
30

Martins, F., Sofiya, L., Sykiotis, G.P. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and
surveillance. Nat Rev Clin Oncol 16, 563–580 (2019). https://doi.org/10.1038/s41571-019-0218-0
31
Duong N, Curley K, Brown A, Campanelli A, Do MA, Levy D, Tantry A, Marriott G, Lu B. Decoy exosomes as a novel
biologic reagent to antagonize inflammation. Int J Nanomedicine. 2019;14:3413-3425
https://doi.org/10.2147/IJN.S196975
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Table 1. Current PD-1 & PD-L1 Checkpoint Inhibiting Immunotherapies15

Immunotherapies

Anti PD-1

Anti PD-L1

Cancers

-Pembrolizumab (Keytruda)

-metastatic non-small cell lung cancer
-head and neck squamous cell carcinoma

-Nivolumab (Opdivo)

-melanoma
-squamous cell lung cancer
-renal cell carcinoma
-Hodgkin’s Lymphoma

-Cemiplimab (Libtayo)

-cutaneous or locally advanced squamous
cell carcinoma

-Atezolizumab (Tecentriq)

-urothelial carcinoma
-non-small cell lung cancer

-Avelumab (Bavencio)

-metastatic merkel-cell carcinoma

-Durvalumab (Imfinzi)

-urothelial carcinoma
-unresectable non-small cell lung cancer

1.4 Project Goals and Constraints
The ultimate goal of our project is to advance immunotherapy by synthesizing an engineered
exosome equipped with a specialized biomarker that will disrupt the PD-1 and PD-L1 pathway
between T-cells and cancer cells and in turn, promote cancer cell death more effectively than the
current antibody-based checkpoint inhibiting treatments.
The first step in this long-term goal and the specific aim of our senior design project is to
successfully engineer an exosome and show that the plasmid vector construct could be integrated
and expressed.
We achieved our specific aim in three phases. In the first phase, we established protocols to grow
and maintain healthy cells. In the second phase, we used a transfection method to integrate the
plasmid construct into two cell lines. Lastly, in the third phase, we used a co-transfection
technique to verify the generation of engineered exosomes in our cells.

15

1.4.1 Phase 1: Learning Mammalian cell culture to Generate Healthy Cells
All group members were new to working in a wet lab environment with mammalian cell
culture procedures, so our first project goal was to learn and practice proper mammalian
cell culture protocols as well as aseptic technique in order to grow and maintain healthy
cells essential for the next phases.
1.4.2 Phase 2: Plasmid vector uptake into 2 cell lines
Next, we aimed to present the successful integration of the plasmid vector into a
mammalian cell line. We selected HepG2, a human liver cancer cell line, to complete a
PEI transfection and used GFP imaging techniques to check for plasmid vector uptake.
In order to further promote the validity of our findings we made it a goal to show proper
plasmid vector expression in a second mammalian cell line. We chose HK-2, human
kidney cells, and used GFP imaging techniques to check for plasmid vector uptake.
1.4.1 Phase 3: Verify vector is incorporated into exosomes
Once plasmid vector uptake was established, we wanted to confirm whether or not the
engineered exosomes were modified with the vector construct as intended. To verify this
we used a co-transfection procedure that would allow us to image the vector construct
uptake locations and separately image the intracelular exosome locations so that we can
overlay them and check for co-occurence.

1.5 Back-Up Plan
Although we practiced aseptic technique, research with mammalian cell lines is susceptible to
bacterial or fungal contamination. Therefore, we kept frozen copies of our cell lines in order to
not jeopardize our project timeline in case of this unforeseen circumstance.

1.6 Significance
The successful completion of this study would result in a novel cancer immunotherapy as this therapy

would be one of the first exosome-based therapies to be used for cancer treatment. The
significance of this treatment is the use of engineered exosomes. These unique nanovesicles increase
the efficacy of cancer therapies due to the natural stability of exosomes in the body, the ability to
penetrate tissue barriers, and biocompatibility of the vesicales to not induce adverse immune
responses. The technology utilized by our proposed exosome therapy could also act as a

16

precedent design to be applied to a number of other therapeutic uses, such as gene therapies and
targeted drug delivery.

1.7 Team Management
We have shared equal responsibility as a team to maintain our cell lines, design and perform
experiments, and analyze data. In addition, Dr. Lu and Annie Brown provided guidance through
regular correspondence and weekly meetings.

1.8 Budget
Table 2. Project Budget
Item

Brand

Cost

DMEM

Gibco

$222.00

Trypsin-EDTA

Gibco

$237.00

PBS

Thermo Fisher
Scientific

$253.00

K-SFM

Thermo Fisher
Scientific/Gibco

$112.00

BPE

Thermo Fisher
Scientific/Gibco

$59.50

EGF

Thermo Fisher
Scientific/Gibco

$107.00

100 mm Plates

Greiner Bio One

$524.63

FuGENE HD

Promega

$482.00

PD-L1 Plasmid Prep

Genscript

$700.00

Fetal Bovine Serum

GE Healthcare

$352.00

Opti-MEM Media

Gibco

$21.98

Serum-free Media
(Ultraculture)

Lonza

$70.00

Total Cost:

$ 3,141.11
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1.9 Research Timeline
Table 3. Project Timeline
Fall Quarter

Winter Quarter

Spring Quarter

Literature Review

X

X

X

Phase 1

X

X

Phase 2

X

Phase 3

X

Write Thesis

X

Present Results

X
X

2. Learning Mammalian Cell Culture to Maintain Healthy
Cells (Research Phase I)
2.1 Design description
Cells and their culture are integral to biomedical research. The ability to reliably and efficiently
assess their wellness is a critical aspect of high-quality and reproducible experimentation.
Knowing this our phase 1 is to establish protocols to generate healthy cells because all research
going forward depends on the success of maintaining several stable cell lines; and adequate
confluency between plate passages. All group members were new to working in a wet lab
environment with mammalian cell culture procedures so we planned to maintain 2 cell lines
through several passages to ensure our ability to generate healthy cells on an ongoing basis.

2.2 Key constraints
The key constraints include the volatility that comes with working with biologics, even when the
same procedure is followed, the cells can react differently. This would need vigilant
communication among group members in order to ensure that our cell culture was healthy since
thawing and restarting a cell line would offset the research timeline by several weeks.
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2.3 Expected Results
Informed by healthy mammalian cell description in literature we would expect to see
- plates that had adequate nutrients (media that was pinkish in color)
- Cells that were “starfished” or adhered to the cell plate bottom and not floating to
show that they were alive and in condition to be used in phases 2 and 3
- Cell plate confluency of about 70-80% observed as percent of plate area covered
with healthy cells

2.4 Materials and methods
Table 4. Materials for Passaging Cells
Material

Company

Brand Model #

*DMEM + 10% FBS + PS
media or
K-SFM+BPE+EGF+ 1% PS

N/A

N/A

Phosphate Buffered Saline
pH 7.4 (PBS)

Thermo Fisher
Scientific/Gibco

AM9625

*Trypsin 0.25% with phenol
red or
Trypsin 0.05% with phenol
red

Thermo Fisher
Scientific/Gibco

15050065

15 mL conical-bottom
centrifuge
tubes

VWR

89039-666

Dish 150mmx20mm

Thermo Fisher Scientific

150468

Methods
1. Check cell plate confluency (70%-80%)
2. Aspirate old media from plate
3. Wash with 3 mL of PBS. Pipet gently into the side of the plate.
4. Aspirate PBS.
5. Add 1.5 mL of trypsin to the plate to detach cells.
- HEP-G2: 0.25% Trypsin*
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- HK-2: 0.05 % Trypsin
6. Incubate at 37°C for 2 minutes.
7. To deactivate trypsin add 4.5mL of...
- HEP-G2: DMEM + 10% FBS + PS media*
- HK-2: K-SFM+BPE+EGF+ 1% PS media
8. Collect cells and media in a 15 mL centrifuge tube, spin at 1500 RPM for 5 minutes.
9. Aspirate off supernatant.
10. Resuspend the pellet in 4 ml of the appropriate cell media.
11. Plate 6 ml on a new cell plate
12. Drop cell suspension solution onto plate (amount depends on size of cell plate and the
desired density on the new cell plate)
13. Incubate at 37°C for 24-72 hours.

2.5 Results

Figure 4. Cell Morphology and Health Status. Images show the difference between Dead and
Healthy cells. Phase images taken at 20x magnification for Dying, Lysed, and Unhealthy. Dead
and Healthy images at 10x magnification.
We accomplished Phase 1 by learning aseptic technique and mammalian cell culture. As a result,
we were able to understand the difference between unhealthy and healthy cells. The data above
represents some images we collected during this phase that showcase our progression to mastery.
The first image shows dying cells demonstrated by their round shape. The Next image depicts
dead cells which are not only round, but are also floating in solution. In the third image, the cells
are lysed; this happened during one of our failed transfection experiments. The fourth image
represents an overall unhealthy cell culture, which contains both healthy but mostly dying cells.
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Next, the last image showcases very healthy and viable cells which have a nice stretched shape
and great confluency across the plate.This is what we would want to see on the cell plate before
we continue on to phase 2 and 3. Hence, the importance of Phase 1 was to prove our ability to
grow healthy and viable mammalian cells.
In phase 1 we also came to learn of the phenotype characteristics of both the HEP-G2 and HK-2
cells when healthy. The figure below shows how HEP-G2 cells had more circular symmetry
when “star-fiched” and had more distinctive cell edges while HK-2 cells were more elongated
when adhered to the cell plate and have less distinctive cell edges.

Figure 5. Phenotype Characteristics of Both the HEP-G2 and HK-2 cells when healthy.

3. Designing and Constructing Vectors of Engineering
Exosomes (Research Phase II)
3.1 Design description
A confluent plate of healthy and viable mammalian cells generated in Phase I is important for
transfection. This will allow for our vector construct to be uptaken by the cells ultimately leading
to the production of our engineered exosomes. We wanted to implement this phase in two
mammalian cell lines, HEP-G2 (a human liver cancer line) and HK (a human kidney cell line) to
prove the feasibility of our design concept.
3.1.1 Vector Construct
Our expression cassette (Fig 6. A), which includes many components integral for the
proper expression of our vector construct, is contained within a pUC57 plasmid vector.
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This construct will be termed PDL1-GFP. The first component is a CMV promoter,
known for its strength in driving gene expression. Next, the vector has a signal peptide
which sends the targeted receptor to the membrane of the exosomes. Following the signal
peptide, is the sequence for PDL1-scFV a truncated version of anti PDL1 that will
present on the surface of the exosomes to bind to PDL1 on cancer cells. The vector also
includes a CD8 hinge region to help with the flexibility of the external portion of the
transmembrane protein and promote binding efficiency with the PDL1 on cancer cells.
The tVSGS sequence is an intramembrane protein. This acts as a link allowing the
receptor to be bound to the external surface of the exosomes and a fluorescent reporter
molecule like eGFP, the next component which will allow us to verify vector construct
(Fig 6.B) uptake and the successful generation of our engineered exosomes (Fig 6.C)
through imaging, to be bound to the internal membrane. Also, the vector includes an
antibiotic resistance component, expressed by the SV-40 promoter which can be used in
the future for transient expression or establishing a stable cell line. Lastly, the poly(A) tail
protects our construct from enzymatic degradation in the cytoplasm and aids in
transcription termination, export of the mRNA from the nucleus, and translation.

Figure 6. Illustration of the Design-Construct. (A) expression cassette (PDL1-GFP) (B) vector
construct, and (C) engineered exosome.
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3.2 Key constraints
The key constraints include cell health, confluency, and amount of transfection agent. It's
important that our cells are healthy, that the cell plate is substantially populated at 70-80%
confluency, and the transfection agents are measured in the right proportions for high
transfection efficiency of our vector construct.

3.3 Expected results
Through imaging, we expect to see green fluorescence which will allow us to assume successful
transfection and integration of our vector construct with the cells’ exosomes.

3.4 Materials and Methods
Table 5. Materials for Transfecting Cells
Material

Company

Brand Model #

*HEP-G2 or HK cells
Polyethylenimine (PEI)

Thermo Fisher
Scientific/Gibco

BMS1003

Opti-MEM

Thermo Fisher
Scientific/Gibco

51985034

DNA sample
(PDL1_pcDNA3.1(+)-C)

Genscript

N/A

6 well plates

Sigma-Aldrich/ Greiner

CLS3516

Microcentrifuge tubes

Sigma-Aldrich/ Eppendorf
Safe-Lock

T9661

1. Follow Passaging HEP-G2 Cells Protocol
2. *Adding Cell Suspension Solution
- HEP-G2: Add 30-40 μl of cell suspension solution from step 10 to two well of a 6-well
cell culture plate
- HK: Add 500-1000 μl of cell suspension solution from step 10 to two well of a 6-well
cell culture plate
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3. Label one of the wells the control and the other one the transfected cells
4. Incubate at 37°C for 24 hours.
5. Check cells for 70-80% confluency.
6. Add 200 µL of OPTIMEM to a microcentrifuge tube
7.*Adding PEI & DNA
- HEP-G2: Add 10 µL of PEI and then 2 ug of DNA to the tube
- HK: Add 2.5 µL of PEI and then 2 ug of DNA to the tube
8. Let the solution sit for 20 minutes
9.Add the entire contents of the solution dropwise to the well designated for transfection.
10. Incubate at 37°C for 24 hours 38

Figure 7. Mechanism of PEI. For transfection, we combined Optimum, growth media, PEI, a
positively charged polymer, and our plasmid to create a transfection solution (Steps 6 & 7
above). Since the plasmid DNA and cell membrane are both negatively charged, encapsulating
the DNA with a positively charged polymer like PEI allows for the plasmid to enter the cell.
Without PEI, the DNA would not be able to enter the cell due to charge repulsion. Once the
DNA is in the cell, the ribosomes can generate our vector construct which can then be
incorporated into exosomes.

Table 6. Materials for Imaging Cells
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Material

Company

Transfected Cell

N/A

Olympus fluorescence
microscope

Olympus-Life Science

Brand Model #
N/A

1. Follow Passaging and Transfecting Cells Protocols
2. Use the Olympus fluorescence microscope and Cell Sense Standard software
3. Capture Phase Images
4. Flip the tab on the microscope to create a black background to see the only the fluorescent
cells by canceling out the white light
5. Capture of the image of the fluorescence cells.
6. Repeat the process for desired cells at different magnifications

3.5 Results
3.5.1 HEP-G2

Figure 8. Transfected HEP-G2 Cells. Cells transfected with PDL1-GFP. Engineered exosomes
marked by GFP. Images taken at 40x.
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These are the results for our transfections into HEPG2. The bottom image is the phase image
which confirms the production of healthy cells. The second image demonstrates that our plasmid
was integrated due to the green fluorescence produced from GFP. Lastly, The overlaid image of
the phase and green fluorescence (shown at the top) allows us to assume that our construct is
concentrated in the right compartment, the cell cytoplasm. These images are what we expected,
and serve as the initial data that we can use to assume our plasmid was transfected and the
engineered exosomes were successfully generated.
3.5.2 HK-2

Figure 9. Transfected HK-2 Cells. Cells transfected with PDL1-GFP. Engineered exosomes
marked by GFP. Images taken at 40x.
Transfection of our vector construct into another mammalian cell line, HK-2, was important to
strengthen our proof of concept by further proving its feasibility. The results are analogous to
HEP-G2. The phase image (on the right) represents a healthy and stretched HK-2 cell necessary
for transfection.From the image in the center, green fluorescence can be seen on the right side of
the cell. Lastly, the overlaid image of the phase and GFP images (on the left), showcase that our
vector construct was produced and has integrated into the cell’s exosomes within the correct
cellular compartment.
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4. Verification of Vector Uptake to Make Engineered
Exosomes (Research Phase III)
4.1 Design description
The imaging of the GFP successfully showed that the exosome construct was transfected into the
both cell lines, HEP-G2 and HK-2. To further verify the transfection of the cells and to confirm
the creation of exosomes, we performed a co-transfection with CD63-RFP on the HEP-G2 cell
line. This RGF plasmid contains an designated exosomes marker that will be used to confirm the
development of the engineered exosomes within the cells. The design goal was the cotransfection
with the RGF plasmid will allow us to demonstrate that the construct, PD-L1-GFP, had
produced engineered exosomes if the plasmid were colocalized. Hence, the resulting RFP and
GFP images were overlaid to clearly show that the exosomes were successfully created with
desired surface protein.

4.2 Key constraints
The key constraints for this part of the project involved the requirements for successful
transfection. These requirements are that the cell cultures were able to reach the necessary
confluency, there were enough transfection reagents to transfect cells, and there was an adequate
number of cells alive after transfection. All of these factors will influence the quality of the
transfection and the images.

4.3 Expected results
The expected results are clear GFP and RFP images where the green and red fluorescence are
colocalized in the cell. Once the images are overlaid the images will produce a yellow
fluorescence to confirm that both plasmids were transfected and the cell is producing exosomes.

4.4 Materials and methods
Table 7. Additional Materials Needed for Co-Transfecting HEP-G2 Cells
Material
Exosome Specific Marker
Plasmid (CD63-RFP)

Company
Genscript

Brand Model #
N/A

Methods
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1. Passage cells following the Passaging Mammalian Cells procedure in Section 2.4
a. Plate cells in the 2 of the 6 wells on the plate
i.
Designate a well for control and a well for both the exosome expression
vector and the exosome marker vector
b. Incubate until 70-80% confluency
2. Transfect the cells following Steps 1-6 of the Transfection procedure in Section 3.4
a. For Step 7, Add 10µL of PEI and 1µL of each plasmid below to a microcentrifuge
tube:
i.
Expression Vector: PDL1_pcDNA3.1(+)-C
ii. Exosome Marker Vector: CD63-RFP
b. Follow the remaining steps, steps 8-10 of the Transfection Procedure in Section
3.4
3. Image the cells following the Imaging procedure in Section 3.4
a. Use the Olympus fluorescence microscope (Waltham, MA)
b. Capture phase contrast, GFP, and RFP images of each well

4.5 Results

Figure 10: HEPG2 cells cotransfected with PDL1-GFP and CD63-RFP. Modified exosomes
represented by GFP and verified with RFP. Images taken at 40x.
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5. Discussion and Conclusion
Our study demonstrates that the delivery of an expression vector to a cell can encourage the
cellular production of exosomes with specialized biomarkers. The engineered exosomes with
specific surface markers have the capability to target certain cellular pathways. In this study, the
PD-L1 ligand on the surface of cancer cells is the ultimate target of the exosomes in order to
disrupt this immune checkpoint pathway that is evaded by cancer cells. In Phase 1 of our study,
we demonstrated the use of mammalian cell culture techniques to maintain healthy HEP-G2 and
HK-2 cell lines. In Phase 2, we confirmed with fluorescent images the successful transfection of
the expression vector in both cell lines to produce engineered exosomes. Lastly in Phase 3, we
verified the cells produced the engineered exosomes with the colocalization of an
exosome-specific marker and the expression vector via fluorescent images. Together, these
results are a proof of concept that mammalian cells can express the vector and produce exosomes
with engineered surface proteins.
Future directions for the next Senior design team include harvesting and isolating the exosomes
to pull them from solution in order to conduct characterization using methods like the nanodrop
to determine size and western blot to confirm that our protein is in the right orientation and
actually on the surface of the exosome. Next, the efficacy of the engineered exosomes needs to
be tested by utilizing a binding assay with cells that express pdl1 on their surface. And lastly, if
this is successful, can be replicated, and adequately peer-reviewed, this project may move on into
the lengthy drug development process which will include pre-clinical, clinical, and post-market
studies.
Moreover, broader applications of this therapy involve functionalizing different receptors on its
surface to target different biomarkers, and the loading of hydrophilic drugs in its core, or
hydrophobic drugs within its membrane for targeted drug delivery.
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6. Engineering Standards and Realistic Constraints
6.1 Social impact
The novelty of exosomes, as biocompatibile nanovesicles with surface modification capability,
will improve upon current immunotherapies that target the PD-1/PD-L1 pathway. We believe
that these superior nanovesicles will increase the efficacy of cancer treatments in turn increase
the survival rate of cancer patients. This belief stems from studies that have shown exosomes to
survive longer in the body, to penetrate tissues better, and to not induce a negative response due
to the biocompatibility of the vesicles. Specifically, the increased half-life of the engineered
exosomes will decrease the required times a patient must receive treatment. Hence, engineered
exosomes could lower the cost of treating cancer while the increased efficacy of therapy could
ultimately improve the survival rate of cancer patients.

6.2 Health and Safety
As this study proposes a novel cancer treatment, it would have to tolerate numerous tests before
it would be a viable option for cancer patients. At this point in the study, the administration to
humans is a long term goal that would be met after many smaller milestones are achieved.
Specifically to our study, the next step to proving the safety of the engineered exosomes would
be testing the toxicity of the treatment in in vitro models. Then, later tests would move to animal
models and hopefully end in a clinical trial and FDA approval of the novel cancer treatment.

6.3 Manufacturability
At this moment in the research, a main focus to improve the manufacturability to increase cell
confluency as a higher cell count would lead to a higher transfection efficacy and a higher
production of exosomes. We propose improving the cell culture method to establish a better
environment for cell growth, especially Hk-2. Secondly, to improve feasibility the optimal
conditions for successful transfection with a high efficiency must be discovered. We suggest
working toward establishing a stable cell line with the PD-L1 exosomes expression vector in the
HK-2 cells. Lastly, the next procedure that must be optimized is the harvesting of the exosomes
process. While we did not reach this step in our study, it is a key step in order to move forward
with these engineered exosomes as a feasible therapeutic. Once these initial processes are
established future work with bioreactors could significantly increase exosome production. Thus,
the manufacturability of this cancer treatment relies on optimizing all steps of the cellular
production of engineered exosomes.
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6.4 Economic
Due to the complexity of cancer, it can be a very hard and expensive disease to treat. The
American Cancer Society predicts that treating cancer will result in an $80.2 billion impact on
the American healthcare system32. This is because the available cancer treatments require
repeated treatment sessions and may never cure the patient of cancer. Thus, these engineered
exosomes have the capability to decrease medical costs by lowering the number of treatments
because of their longer half-life and increase efficacy compared to conventional cancer therapies.
Also, it must be noted that the biocompatibility of the nanovesicles could lower treatment cost by
decreasing the need for extra medications to limit the adverse immune responses.

6.5 Ethical implications
Cancer impacts people all over the world. The need for a cure and not a treatment is more
imperative than ever before. That is why we believe in this project as this novel therapy using
engineered exosomes could be the solution to this worldwide problem. We understand that
people are fighting cancer very successfully, however, they only enter remission and have to live
with the disease. Thus, this project along with other similar studies are working to develop a
novel cancer treatment that will improve a patient's quality of life, which is the ethical
responsibility of all people in this field.
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Appendix
A1: Making Media: DMEM + 10% FBS + PS

Table A1-1: Materials for Making Media
Material

Company

Brand Model #

Dulbecco’s Modified Eagle
Medium with L-Glutamine
(DMEM)

Thermo Fisher
Scientific/Gibco

11965092

Fetal Bovine Serum (FBS)

Thermo Fisher
Scientific/Gibco

10438034

Penicillin-Streptomycin (PS)

Thermo Fisher
Scientific/Gibco

15140122

1. Add 50 mL of FBS into a 500ml bottle of DMEM with L-Glutamine.
2. Add 5 mL of PS to the combined FBS and DMEM.
3. Mix thoroughly.
4. Store at 4°C until needed.

A2: Making Media: K-SFM+BPE+EGF+ 1% PS

Table A2-1: Materials for Making Media
Material

Company

Brand Model #

Keratinocyte SFM (K-SFM)

Thermo Fisher
Scientific/Gibco

17005042

Bovine Pituitary Extract
(BPE)

Thermo Fisher
Scientific/Gibco

13028014

EGF Recombinant Human
Protein Solution (EGF)

Thermo Fisher
Scientific/Gibco

PHG0311L
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Penicillin-Streptomycin (PS)

Thermo Fisher
Scientific/Gibco

15140122

1. Add 25 mg BPE to a 500ml bottle of K-SFM.
2. Add 0.005 mg of EGF to the combined FBS and DMEM.
3. Add 5 ml of PS to the solution
3. Mix thoroughly.
4. Store at 4°C until needed.
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